{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T17:05:29Z","timestamp":1776272729254,"version":"3.50.1"},"reference-count":245,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T00:00:00Z","timestamp":1559606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.00443","type":"journal-article","created":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T06:17:03Z","timestamp":1559629023000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas"],"prefix":"10.3389","volume":"9","author":[{"given":"Stefania","family":"Crisci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"Di Francia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Mele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina","family":"Ronga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosaria","family":"De Filippi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Berretta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,6,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1182\/blood-2005-03-1306","article-title":"T-cell non-Hodgkin lymphoma","volume":"107","author":"Rizvi","year":"2006","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1080\/17474086.2017.1318053","article-title":"Lymphoma classification update: B-cell non-Hodgkin lymphomas","volume":"10","author":"Jiang","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/bjh.15412","article-title":"How I manage patients with relapsed\/refractory diffuse large B cell lymphoma","volume":"182","author":"Gisselbrecht","year":"2018","journal-title":"Br J Haematol"},{"key":"B5","first-page":"113","article-title":"Advances in the diagnosis and treatment of childhood and adolescent B-cell non-Hodgkin lymphoma","volume":"13","author":"El-Mallawany","year":"2015","journal-title":"Clin Adv Hematol Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.clml.2017.11.003","article-title":"How to approach a Hodgkin lymphoma patient with relapse after autologous SCT: allogeneic SCT","volume":"18","author":"Mei","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B7","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3322\/caac.21438","article-title":"Hodgkin lymphoma: a review and update on recent progress","volume":"68","author":"Shanbhag","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1540044","article-title":"Clinical prognostic scores are poor predictors of overall survival in various types of malignant lymphomas","author":"Biccler","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15783","article-title":"Novel targeted therapeutic agents for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma","author":"Barth","year":"2019","journal-title":"Br J Haematol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1080\/14656566.2019.1582643","article-title":"Choosing the right pharmacotherapy for non-Hodgkin's lymphoma: does one size fit all?","volume":"20","author":"Al Juhaishi","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"B11","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s11912-009-0051-1","article-title":"The future of small molecule inhibitors in lymphoma","volume":"11","author":"Gerecitano","year":"2009","journal-title":"Curr Oncol Rep"},{"key":"B12","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s11899-018-0485-3","article-title":"Combining biology and chemistry for a new take on chemotherapy: antibody-drug conjugates in hematologic malignancies","volume":"13","author":"Ma","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"B13","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/annonc\/mdx061","article-title":"ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia","volume":"29","author":"Ladetto","year":"2018","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/17474086.2017.1271318","article-title":"Mature aggressive B-cell lymphoma across age groups - molecular advances and therapeutic implications","volume":"10","author":"Lange","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1177\/2040620717738740","article-title":"The evolving role of targeted biological agents in the management of indolent B-cell lymphomas","volume":"8","author":"Wang","year":"2017","journal-title":"Ther Adv Hematol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.21037\/aol.2017.08.03","article-title":"Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma","volume":"1","author":"Merryman","year":"2017","journal-title":"Blood Adv"},{"key":"B17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/17474086.2017.1268046","article-title":"New targeted therapies for malignant lymphoma based on molecular heterogeneity","volume":"10","author":"Horn","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11899-017-0383-0","article-title":"Small molecule inhibitors in chronic lymphocytic lymphoma and B cell non-Hodgkin lymphoma","volume":"12","author":"Rosenthal","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/bjh.15695","article-title":"Novel therapeutic agents for relapsed classical Hodgkin lymphoma","volume":"184","author":"von Keudell","year":"2019","journal-title":"Br J Haematol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/s11899-017-0396-8","article-title":"An update on the use of immunotherapy in the treatment of lymphoma","volume":"12","author":"Marron","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"key":"B21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.bbcan.2018.12.002","article-title":"Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment","volume":"1871","author":"Wang","year":"2018","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.clim.2017.09.016","article-title":"CAR T cell immunotherapy in hematology and beyond","volume":"186","author":"Rossig","year":"2018","journal-title":"Clin Immunol"},{"key":"B23","first-page":"73","article-title":"CAR T-cell therapy in non-Hodgkin lymphoma patients","volume":"33","author":"Copelan","year":"2019","journal-title":"Oncology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.beha.2018.07.011","article-title":"The promise of CAR T-cell therapy in aggressive B-cell lymphoma","volume":"31","author":"Nair","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"93","DOI":"10.21037\/tcr.2017.01.08","article-title":"The role of novel immunotherapies in non-Hodgkin lymphoma","volume":"6","author":"Pishko","year":"2017","journal-title":"Transl Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/978-1-4939-8958-4_2","article-title":"Cancer immunotherapy: the dawn of antibody cocktails","volume":"1904","author":"Marrocco","year":"2019","journal-title":"Methods Mol Biol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e0165839","DOI":"10.1371\/journal.pone.0165839","article-title":"Fabrication of bacteria environment cubes with dry lift-off fabrication process for enhanced nitrification","volume":"11","author":"Samarasinghe","year":"2016","journal-title":"PLoS ONE"},{"key":"B28","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/bjh.14534","article-title":"A Phase 1\/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab","volume":"177","author":"Sawas","year":"2017","journal-title":"Br J Haematol"},{"key":"B29","first-page":"217","volume":"30","year":"2007","journal-title":"Onkologie"},{"key":"B30","doi-asserted-by":"publisher","first-page":"3644","DOI":"10.1038\/sj.onc.1210380","article-title":"Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia","volume":"26","author":"Alinari","year":"2007","journal-title":"Oncogene"},{"key":"B31","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/ejh.12825","article-title":"Alemtuzumab consolidation in chronic lymphocytic leukaemia: a Phase I\/II multicentre trial","volume":"98","author":"Al-Sawaf","year":"2017","journal-title":"Eur J Haematol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/2040620712443076","article-title":"Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma","volume":"3","author":"Vaklavas","year":"2012","journal-title":"Ther Adv Hematol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1177\/2040620718786833","article-title":"Update on the role of brentuximab vedotin in classical Hodgkin lymphoma","volume":"9","author":"Tomassetti","year":"2018","journal-title":"Ther Adv Hematol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.2147\/OTT.S141053","article-title":"Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review","volume":"11","author":"Donato","year":"2018","journal-title":"Onco Targets Ther"},{"key":"B35","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.critrevonc.2016.11.009","article-title":"Brentuximab vedotin for treatment of non-Hodgkin lymphomas: a systematic review","volume":"109","author":"Berger","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/s11899-016-0345-y","article-title":"CD30 and CD30-targeted therapies in Hodgkin lymphoma and other B cell lymphomas","volume":"11","author":"Bhatt","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1182\/blood-2013-01-481713","article-title":"CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma","volume":"122","author":"Bhatt","year":"2013","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1158\/1535-7163.MCT-16-0233","article-title":"ADCT-301, a Pyrrolobenzodiazepine (PBD) dimer-containing Antibody-Drug Conjugate (ADC) targeting CD25-expressing hematological malignancies","volume":"15","author":"Flynn","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"B39","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1182\/blood.V124.21.4491.4491","article-title":"Pre-clinical activity of Adct-301, a novel Pyrrolobenzodiazepine (PBD) dimer-containing Antibody Drug Conjugate (ADC) targeting CD25-expressing hematological malignancies","volume":"124","author":"Flynn","year":"2014","journal-title":"Blood"},{"key":"B40","first-page":"133","article-title":"CD52 and CD25 are highly expressed in childhood non-Hodgkin's lymphoma and may be excellent targets for immunotherapy with alemtuzumab and\/or denileukin diftitox, respectively","volume":"16","author":"Satwani","year":"2005","journal-title":"Ann Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1200\/JCO.2008.21.3017","article-title":"Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma","volume":"27","author":"Advani","year":"2009","journal-title":"J Clin Oncol"},{"key":"B42","first-page":"69","article-title":"A gene signature predicts sensitivity to the partial CD40 agonist, dacetuzumab (SGN-40), in patients with diffuse large B-cell lymphoma","author":"Burington","year":"2009","journal-title":"Cancer Res"},{"key":"B43","doi-asserted-by":"crossref","first-page":"832a-a","DOI":"10.1182\/blood.V106.11.2966.2966","article-title":"Humanized anti CD-40 antibody SGN-40 effectively induces cytotoxicity against chronic lymphocytic leukemia (CLL) cells through antibody mediated cytotoxicity and demonstrates modest biologic evidence of CD40 activation","volume":"106","author":"Gowda","year":"2005","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.3109\/10428194.2012.681655","article-title":"Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia","volume":"53","author":"Byrd","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"B45","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood.V128.22.615.615","article-title":"Obinutuzumab plus bendamustine followed by obinutuzumab maintenance prolongs overall survival compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma: updated results of the GADOLIN Study","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20","volume":"177","author":"Teeling","year":"2006","journal-title":"J Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","article-title":"Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas","volume":"104","author":"Teeling","year":"2004","journal-title":"Blood"},{"key":"B48","first-page":"102","article-title":"A Phase III study of ofatumumab vs rituximab in indolent B-cell non-Hodgkin lymphoma relapsed after rituximab containing therapy (homer): results of the interim analysis","volume":"101","author":"Maloney","year":"2016","journal-title":"Haematologica"},{"key":"B49","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1182\/blood.V120.21.56.56","article-title":"A Phase I study of the anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A targeting CD79b in relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL)","volume":"120","author":"Palanca-Wessels","year":"2012","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1182\/blood-2018-99-118551","article-title":"Polatuzumab vedotin (pola) plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed\/Refractory (R\/R) Diffuse Large B-Cell Lymphoma (DLBCL): updated results of a Phase (Ph) Ib\/II study","volume":"132","author":"Sehn","year":"2018","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1358\/dof.2016.041.07.2505619","article-title":"Polatuzumab vedotin anti-CD79b antibody-drug conjugate treatment of hematologic malignancies","volume":"41","author":"Gajdosik","year":"2016","journal-title":"Drugs Future"},{"key":"B52","first-page":"128","article-title":"Polatuzumab vedotin combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in patients with Relapsed or Refractory (R\/R) Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL): preliminary results of a Phase Ib\/II dose-escalation study","author":"Herrera","year":"2016","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1182\/blood.V128.22.1856.1856","article-title":"Polatuzumab vedotin combined with Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone (G-CHP) for patients with previously untreated Diffuse Large B-Cell Lymphoma (DLBCL): preliminary results of a Phase Ib\/II dose-escalation study","volume":"128","author":"Forero-Torres","year":"2016","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1182\/blood.V126.23.2726.2726","article-title":"Polatuzumab vedotin combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for patients with previously untreated Diffuse Large B-Cell Lymphoma (DLBCL): preliminary results of a Phase Ib dose-escalation","volume":"126","author":"Bartlett","year":"2015","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3389\/fimmu.2017.01245","article-title":"Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going?","volume":"8","author":"Marshall","year":"2017","journal-title":"Front Immunol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv Ther"},{"key":"B57","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1182\/blood.V126.23.3980.3980","article-title":"Ublituximab (TG-1101), a novel glycoengineered anti-CD20 monoclonal antibody, in combination with ibrutinib is highly active in patients with relapsed and\/or refractory mantle cell lymphoma; results of a Phase II trial","volume":"126","author":"Kolibaba","year":"2015","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/35101072","article-title":"Improving the efficacy of antibody-based cancer therapies","volume":"1","author":"Carter","year":"2001","journal-title":"Nat Rev Cancer"},{"key":"B59","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s11899-018-0484-4","article-title":"Checkpoint inhibitors Hodgkin lymphoma and non-Hodgkin lymphoma","volume":"13","author":"Hu","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"B60","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1182\/asheducation-2017.1.618","article-title":"Harnessing the power of the immune system in non-Hodgkin lymphoma: immunomodulators, checkpoint inhibitors, and beyond","volume":"2017","author":"Ansell","year":"","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1080\/17474086.2016.1242404","article-title":"Immune checkpoint inhibitors in Hodgkin and non-Hodgkin lymphoma: how they work and when to use them","volume":"9","author":"Savage","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.intimp.2018.12.006","article-title":"Checkpoint-modulating immunotherapies in tumor treatment: targets, drugs, and mechanisms","volume":"67","author":"Sun","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"B63","first-page":"13","article-title":"PD-1 targeted therapy in lymphomas","volume":"182","author":"Ansell","year":"2018","journal-title":"Br J Haematol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"B65","first-page":"4055","article-title":"PD-1 blockade with pembrolizumab in relapsed low grade non-Hodgkin lymphoma","volume":"130","author":"Ding","year":"2017","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","first-page":"13260","DOI":"10.18632\/oncotarget.7177","article-title":"Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective","volume":"7","author":"Villasboas","year":"2016","journal-title":"Oncotarget"},{"key":"B67","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1080\/14712598.2018.1522300","article-title":"Pembrolizumab for the first-line treatment of non-small cell lung cancer","volume":"18","author":"Ninomiya","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","article-title":"Nivolumab for metastatic renal cell carcinoma: results of a randomized Phase II trial","volume":"33","author":"Motzer","year":"2015","journal-title":"J Clin Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"B71","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11864-016-0401-9","article-title":"Checkpoint inhibitors and other immune therapies for Hodgkin and non-Hodgkin lymphoma","volume":"17","author":"Matsuki","year":"2016","journal-title":"Curr Treat Options Oncol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/S0960-9822(02)00506-7","article-title":"Lymphocyte activation: T-cell regulation by CTLA-4","volume":"6","author":"Linsley","year":"1996","journal-title":"Curr Biol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S1074-7613(00)80480-X","article-title":"Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement","volume":"4","author":"Linsley","year":"1996","journal-title":"Immunity"},{"key":"B74","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S1074-7613(94)80021-9","article-title":"Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors","volume":"1","author":"Linsley","year":"1994","journal-title":"Immunity"},{"key":"B75","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","article-title":"PD-1 expression and clinical PD-1 blockade in B-cell lymphomas","volume":"131","author":"Xu-Monette","year":"2018","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front Pharmacol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1982423","DOI":"10.1155\/2018\/1982423","article-title":"Immune checkpoint inhibitors to treat malignant lymphomas","volume":"2018","author":"Witkowska","year":"2018","journal-title":"J Immunol Res"},{"key":"B78","doi-asserted-by":"publisher","first-page":"5532","DOI":"10.1038\/s41598-017-06002-8","article-title":"Molecular mechanism of PD-1\/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab","volume":"7","author":"Lee","year":"2017","journal-title":"Sci Rep"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1158\/1078-0432.CCR-17-2777","article-title":"Ipilimumab plus lenalidomide after allogeneic and autologous stem cell transplantation for patients with lymphoid malignancies","volume":"24","author":"Khouri","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm Phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a Phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"key":"B82","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood.V124.21.290.290","article-title":"PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a Phase 1b study (KEYNOTE-013)","volume":"124","author":"Moskowitz","year":"2014","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.humpath.2016.03.005","article-title":"Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas","volume":"54","author":"Menter","year":"2016","journal-title":"Hum Pathol"},{"key":"B85","first-page":"17","article-title":"Kymriah: A sign of more difficult decisions to come","volume":"27","author":"Silverman","year":"2018","journal-title":"Manag Care"},{"key":"B86","first-page":"28","article-title":"Novartis's Kymriah: harnessing immune system comes with worry about reining in costs","volume":"26","author":"Morrow","year":"2017","journal-title":"Manag Care"},{"key":"B87","first-page":"177","volume":"59","year":"2017","journal-title":"Med Lett Drugs Ther"},{"key":"B88","doi-asserted-by":"publisher","first-page":"8049","DOI":"10.1158\/0008-5472.CAN-08-2268","article-title":"Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia","volume":"68","author":"Horton","year":"2008","journal-title":"Cancer Res"},{"key":"B89","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s40425-018-0460-5","article-title":"Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance","volume":"6","author":"Boyiadzis","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B90","first-page":"e122","volume":"60","year":"2018","journal-title":"Med Lett Drugs Ther"},{"key":"B91","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"B92","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"B93","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13045-018-0593-5","article-title":"CD19 CAR-T cell therapy for relapsed\/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies","volume":"11","author":"Zhang","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1146\/annurev-pharmtox-010814-124844","article-title":"Therapeutic potential of T cell Chimeric Antigen Receptors (CARs) in cancer treatment: counteracting off-tumor toxicities for safe CAR T cell therapy","volume":"56","author":"Gross","year":"2016","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1002\/ajh.25445","article-title":"Toxicities of CD19 CAR-T cell immunotherapy","volume":"94","author":"Hirayama","year":"2019","journal-title":"Am J Hematol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.critrevonc.2014.08.003","article-title":"Bispecific antibody platforms for cancer immunotherapy","volume":"92","author":"Lameris","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.drudis.2015.02.008","article-title":"Bispecific antibodies","volume":"20","author":"Kontermann","year":"2015","journal-title":"Drug Discov Today"},{"key":"B98","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13045-015-0227-0","article-title":"Bispecific antibodies and their applications","volume":"8","author":"Fan","year":"2015","journal-title":"J Hematol Oncol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ctrv.2018.04.002","article-title":"Bispecific antibodies in haematological malignancies","volume":"65","author":"Viardot","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"B100","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1177\/1087057114561405","article-title":"Characterization of bispecific T-cell Engager (BiTE) antibodies with a high-capacity T-cell dependent cellular cytotoxicity (TDCC) assay","volume":"20","author":"Nazarian","year":"2015","journal-title":"J Biomol Screen"},{"key":"B101","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/cpt.651","article-title":"Translation and clinical development of bispecific T-cell engaging antibodies for cancer treatment","volume":"101","author":"Yuraszeck","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"B102","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2017-06-741058","article-title":"Redirecting T cells to hematological malignancies with bispecific antibodies","volume":"131","author":"Velasquez","year":"2018","journal-title":"Blood"},{"key":"B103","first-page":"1522","article-title":"A Phase 1 study investigating the combination of AFM13 and the monoclonal anti-PD-1 antibody pembrolizumab in patients with relapsed\/refractory Hodgkin lymphoma after brentuximab vedotin failure: data from the dose escalation part of the study","volume":"130","author":"Ansell","year":"2017","journal-title":"Blood"},{"key":"B104","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.bbrc.2018.12.175","article-title":"CD47\/SIRPalpha blocking enhances CD19\/CD3-bispecific T cell engager antibody-mediated lysis of B cell malignancies","volume":"509","author":"Xu","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s10637-015-0289-4","article-title":"Blinatumomab for the treatment of acute lymphoblastic leukemia","volume":"33","author":"Kaplan","year":"2015","journal-title":"Invest New Drugs"},{"key":"B106","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jmb.2010.04.001","article-title":"Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion","volume":"399","author":"Johnson","year":"2010","journal-title":"J Mol Biol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"4542","DOI":"10.1182\/blood-2010-09-306449","article-title":"Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma","volume":"117","author":"Moore","year":"2011","journal-title":"Blood"},{"key":"B108","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1182\/blood-2011-02-337691","article-title":"DARTs take aim at BiTEs","volume":"117","author":"Rader","year":"2011","journal-title":"Blood"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-Cell Engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: final results from a Phase I study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J Clin Oncol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"key":"B111","first-page":"299","article-title":"Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 2: adoptive cellular immunotherapy, small-molecule inhibitors, and immunomodulation","volume":"29","author":"Siddiqi","year":"2015","journal-title":"Oncology"},{"key":"B112","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s11899-018-0467-5","article-title":"Small-molecule inhibitors for the treatment of diffuse large B cell lymphoma","volume":"13","author":"Rhodes","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"B113","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nri1808","article-title":"ITAM-mediated tonic signalling through pre-BCR and BCR complexes","volume":"6","author":"Monroe","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S0968-0004(97)01061-X","article-title":"Phosphoinositide 3-kinases: a conserved family of signal transducers","volume":"22","author":"Vanhaesebroeck","year":"1997","journal-title":"Trends Biochem Sci"},{"key":"B115","doi-asserted-by":"crossref","first-page":"4596","DOI":"10.4049\/jimmunol.155.10.4596","article-title":"Phosphorylated immunoreceptor signaling motifs (ITAMs) exhibit unique abilities to bind and activate Lyn and Syk tyrosine kinases","volume":"155","author":"Johnson","year":"1995","journal-title":"J Immunol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1002\/j.1460-2075.1994.tb06387.x","article-title":"Tyrosine kinases Lyn and Syk regulate B cell receptor-coupled Ca2+ mobilization through distinct pathways","volume":"13","author":"Takata","year":"1994","journal-title":"EMBO J"},{"key":"B117","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, Phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1200\/JCO.2011.35.9695","article-title":"Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial","volume":"30","author":"Pettitt","year":"2012","journal-title":"J Clin Oncol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1182\/blood-2014-12-617522","article-title":"Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a Phase 1b\/2 study","volume":"126","author":"Jaglowski","year":"2015","journal-title":"Blood"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S1470-2045(14)70335-3","article-title":"Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, Phase 2 study","volume":"15","author":"Burger","year":"2014","journal-title":"Lancet Oncol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N Engl J Med"},{"key":"B122","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1182\/blood.V126.23.832.832","article-title":"The BTK inhibitor, Bgb-3111, is safe, tolerable, and highly active in patients with relapsed\/ refractory B-cell malignancies: initial report of a Phase 1 first-in-human trial","volume":"126","author":"Tam","year":"2015","journal-title":"Blood"},{"key":"B123","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1182\/blood-2015-08-664086","article-title":"A Phase 1 clinical trial of the selective BTK inhibitor ONO\/GS-4059 in relapsed and refractory mature B-cell malignancies","volume":"127","author":"Walter","year":"2016","journal-title":"Blood"},{"key":"B124","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.3324\/haematol.2015.140806","article-title":"Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed\/refractory chronic lymphocytic leukemia","volume":"101","author":"Brown","year":"2016","journal-title":"Haematologica"},{"key":"B125","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/1756-8722-6-59","article-title":"Ibrutinib and novel BTK inhibitors in clinical development","volume":"6","author":"Akinleye","year":"2013","journal-title":"J Hematol Oncol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40265-016-0565-4","article-title":"The emerging role of PI3K inhibitors in the treatment of hematological malignancies: preclinical data and clinical progress to date","volume":"76","author":"Seiler","year":"2016","journal-title":"Drugs"},{"key":"B127","doi-asserted-by":"publisher","first-page":"7520","DOI":"10.1200\/JCO.2018.36.15_suppl.7520","article-title":"Phase I\/II clinical trial of ibrutinib and buparlisib in relapsed\/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma","volume":"36","author":"Batlevi","year":"2018","journal-title":"J Clin Oncol"},{"key":"B128","first-page":"4319","article-title":"A Phase II clinical trial of the pan PI3K inhibitor, buparlisib, for the treatment of relapsed and refractory chronic lymphocytic leukemia: canadian cancer trials group IND. 216","volume":"130","author":"Assouline","year":"2017","journal-title":"Blood"},{"key":"B129","first-page":"126","article-title":"An open-label Phase II study of buparlisib (BKM120) in patients with relapsed and refractory Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL) and Follicular Lymphoma (FL)","author":"Younes","year":"2015","journal-title":"Blood"},{"key":"B130","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.2147\/DDDT.S142406","article-title":"Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib","volume":"12","author":"Krause","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"B131","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1093\/annonc\/mdx289","article-title":"Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J Clin Oncol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.clml.2018.11.021","article-title":"Optimal management of adverse events from copanlisib in the treatment of patients with non-Hodgkin lymphomas","volume":"19","author":"Cheson","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B134","first-page":"35","article-title":"A closer look at copanlisib","volume":"16","author":"Dreyling","year":"2018","journal-title":"Clin Adv Hematol Oncol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1016\/S1470-2045(14)70052-X","article-title":"Idelalisib: targeting PI3Kdelta in B-cell malignancies","volume":"15","author":"Gilbert","year":"2014","journal-title":"Lancet Oncol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1158\/1078-0432.CCR-14-2522","article-title":"FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma","volume":"21","author":"Miller","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B137","doi-asserted-by":"publisher","first-page":"547","DOI":"10.2146\/ajhp150281","article-title":"Idelalisib for treatment of B-cell malignancies","volume":"73","author":"Do","year":"2016","journal-title":"Am J Health Syst Pharm"},{"key":"B138","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/BLCTT.S73530","article-title":"Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas","volume":"6","author":"Madanat","year":"2016","journal-title":"Blood Lymphat Cancer"},{"key":"B139","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"key":"B140","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1093\/annonc\/mdx028","article-title":"Phase II study of idelalisib, a selective inhibitor of PI3Kdelta, for relapsed\/refractory classical Hodgkin lymphoma","volume":"28","author":"Gopal","year":"2017","journal-title":"Ann Oncol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1182\/blood-2016-12-757740","article-title":"Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy","volume":"129","author":"Gopal","year":"2017","journal-title":"Blood"},{"key":"B142","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1517\/14656566.2016.1135130","article-title":"Idelalisib for the treatment of non-Hodgkin lymphoma","volume":"17","author":"Graf","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"B143","doi-asserted-by":"publisher","first-page":"e156","DOI":"10.3324\/haematol.2016.151738","article-title":"Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a Phase 2 study","volume":"102","author":"Salles","year":"2017","journal-title":"Haematologica"},{"key":"B144","first-page":"4050","article-title":"Increased risk of toxicity with novel PI3K delta inhibitor combinations compared with standard use in non-Hodgkin lymphoma patients","volume":"130","author":"Williams","year":"2017","journal-title":"Blood"},{"key":"B145","first-page":"195","article-title":"Pi3k delta inhibitor pulmonary toxicity","author":"Bender","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"B146","first-page":"821","article-title":"PI3K inhibitors: understanding toxicity mechanisms and management","volume":"31","author":"Greenwell","year":"2017","journal-title":"Oncology"},{"key":"B147","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13045-017-0512-1","article-title":"Syk inhibitors in clinical development for hematological malignancies","volume":"10","author":"Liu","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B148","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1124\/jpet.114.218164","article-title":"The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer","volume":"351","author":"Coffey","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"B149","doi-asserted-by":"publisher","first-page":"43881","DOI":"10.18632\/oncotarget.6316","article-title":"Cerdulatinib, a novel dual SYK\/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma","volume":"6","author":"Ma","year":"2015","journal-title":"Oncotarget"},{"key":"B150","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1158\/1078-0432.CCR-16-1662","article-title":"The dual Syk\/JAK inhibitor cerdulatinib antagonizes B-cell receptor and microenvironmental signaling in chronic lymphocytic leukemia","volume":"23","author":"Blunt","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B151","doi-asserted-by":"publisher","first-page":"12953","DOI":"10.18632\/oncotarget.14588","article-title":"Dual SYK\/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment","volume":"8","author":"Guo","year":"2017","journal-title":"Oncotarget"},{"key":"B152","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/jcph.794","article-title":"PRT062607 achieves complete inhibition of the spleen tyrosine kinase at tolerated exposures following oral dosing in healthy volunteers","volume":"57","author":"Coffey","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"B153","doi-asserted-by":"publisher","first-page":"8531","DOI":"10.1200\/jco.2015.33.15_suppl.8531","article-title":"Phase 1 open-label dose escalation study of the dual SYK\/JAK inhibitor cerdulatinib (PRT062070) in patients with relapsed\/refractory B-cell malignancies: safety profile and clinical activity","volume":"33","author":"Flinn","year":"2015","journal-title":"J Clin Oncol"},{"key":"B154","first-page":"126","article-title":"Clinical and correlative results of a Phase 1 study of cerdulatinib (PRT062070) a dual SYK\/JAK inhibitor in patients with relapsed\/refractory B cell malignancies","author":"Hamlin","year":"2015","journal-title":"Blood"},{"key":"B155","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.1021\/jm500228a","article-title":"Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase","volume":"57","author":"Currie","year":"2014","journal-title":"J Med Chem"},{"key":"B156","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1182\/blood.V128.22.2963.2963","article-title":"Results of a Phase 2 trial evaluating efficacy and safety of entospletinib (GS-9973) in patients with mantle cell lymphoma","volume":"128","author":"Sharman","year":"2016","journal-title":"Blood"},{"key":"B157","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1124\/jpet.106.109058","article-title":"R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation","volume":"319","author":"Braselmann","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"B158","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejca.2015.10.005","article-title":"A Phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)","volume":"54","author":"Flinn","year":"2016","journal-title":"Eur J Cancer"},{"key":"B159","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"key":"B160","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1038\/leu.2013.37","article-title":"Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia","volume":"27","author":"Herman","year":"2013","journal-title":"Leukemia"},{"key":"B161","doi-asserted-by":"publisher","first-page":"5947","DOI":"10.1016\/j.bmcl.2016.10.087","article-title":"Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK)","volume":"26","author":"Lam","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"B162","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/0092-8674(94)90396-4","article-title":"The ubiquitin-proteasome proteolytic pathway","volume":"79","author":"Ciechanover","year":"1994","journal-title":"Cell"},{"key":"B163","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1152\/physrev.00027.2001","article-title":"The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction","volume":"82","author":"Glickman","year":"2002","journal-title":"Physiol Rev"},{"key":"B164","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1172\/JCI71602","article-title":"Emerging therapies targeting the ubiquitin proteasome system in cancer","volume":"124","author":"Weathington","year":"2014","journal-title":"J Clin Invest"},{"key":"B165","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2174\/1386207320666170710124746","article-title":"The small molecules targeting ubiquitin-proteasome system for cancer therapy","volume":"20","author":"Ao","year":"2017","journal-title":"Comb Chem High Throughput Screen"},{"key":"B166","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1517\/14728222.2013.815728","article-title":"Targeting the ubiquitin-proteasome system for cancer therapy","volume":"17","author":"Shen","year":"2013","journal-title":"Expert Opin Ther Targets"},{"key":"B167","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/j.1349-7006.2008.01013.x","article-title":"Targeting the ubiquitin-proteasome system for cancer therapy","volume":"100","author":"Yang","year":"2009","journal-title":"Cancer Sci"},{"key":"B168","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s10555-017-9705-x","article-title":"Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing","volume":"36","author":"Soave","year":"2017","journal-title":"Cancer Metastasis Rev"},{"key":"B169","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2174\/157018007779422541","article-title":"Bortezomib: Proteasome inhibition as a novel mechanism of cancer therapy-implications for hematological malignancies","volume":"4","author":"Mikhael","year":"2007","journal-title":"Lett Drug Des Discov"},{"key":"B170","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3324\/haematol.2008.001537","article-title":"A Phase II study of bortezomib in patients with MALT lymphoma","volume":"94","author":"Troch","year":"2009","journal-title":"Haematologica"},{"key":"B171","doi-asserted-by":"publisher","first-page":"7313","DOI":"10.1158\/1078-0432.CCR-11-0636","article-title":"Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies","volume":"17","author":"Lee","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B172","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","article-title":"Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer","volume":"70","author":"Kupperman","year":"2010","journal-title":"Cancer Res"},{"key":"B173","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/2040620717710171","article-title":"The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma","volume":"8","author":"Brayer","year":"2017","journal-title":"Ther Adv Hematol"},{"key":"B174","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40292-018-0256-1","article-title":"Evaluation of cardiovascular toxicity associated with treatments containing proteasome inhibitors in multiple myeloma therapy","volume":"25","author":"Iannaccone","year":"2018","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"B175","first-page":"192","article-title":"Intermediate-term global toxicity analysis of proteasome inhibitor-based antihumoral therapy","volume":"11","author":"Schmidt","year":"2011","journal-title":"Am J Transpl"},{"key":"B176","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/SPC.0000000000000266","article-title":"Proteasome inhibitor-induced gastrointestinal toxicity","volume":"11","author":"Stansborough","year":"2017","journal-title":"Curr Opin Support Palliat Care"},{"key":"B177","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2174\/156800911794519725","article-title":"Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs)","volume":"11","author":"Kuhn","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"key":"B178","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s11912-004-0022-5","article-title":"Mammalian target of rapamycin (mTOR) inhibitors","volume":"6","author":"Dutcher","year":"2004","journal-title":"Curr Oncol Rep"},{"key":"B179","doi-asserted-by":"publisher","first-page":"621","DOI":"10.2174\/1568009043332718","article-title":"Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents","volume":"4","author":"Rao","year":"2004","journal-title":"Curr Cancer Drug Targets"},{"key":"B180","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2174\/157488707780599366","article-title":"Clinical development of mTOR inhibitors: a focus on lymphoma","volume":"2","author":"Smith","year":"2007","journal-title":"Rev Recent Clin Trials"},{"key":"B181","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/path.1725","article-title":"Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR","volume":"205","author":"Dutton","year":"2005","journal-title":"J Pathol"},{"key":"B182","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1016\/S2352-3026(16)30047-3","article-title":"mTOR inhibition in diffuse large B-cell lymphoma: new hope?","volume":"3","author":"Hess","year":"2016","journal-title":"Lancet Haematol"},{"key":"B183","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/ajh.24671","article-title":"Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma","volume":"92","author":"Bennani","year":"2017","journal-title":"Am J Hematol"},{"key":"B184","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/sj.leu.2404471","article-title":"Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma","volume":"21","author":"Haritunians","year":"2007","journal-title":"Leukemia"},{"key":"B185","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s00280-017-3499-y","article-title":"Pharmacokinetically-targeted dosed everolimus maintenance therapy in lymphoma patients","volume":"81","author":"Schoch","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"B186","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40164-018-0103-z","article-title":"Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma","volume":"7","author":"Johnston","year":"2018","journal-title":"Exp Hematol Oncol"},{"key":"B187","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/ajh.21664","article-title":"A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma","volume":"85","author":"Johnston","year":"2010","journal-title":"Am J Hematol"},{"key":"B188","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1002\/cncr.25005","article-title":"The treatment of recurrent\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation","volume":"116","author":"Zent","year":"2010","journal-title":"Cancer"},{"key":"B189","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.3109\/10428194.2013.823492","article-title":"Combination of rituximab and mammalian target of rapamycin inhibitor everolimus (RAD001) in diffuse large B-cell lymphoma","volume":"55","author":"Xu","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"B190","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3324\/haematol.2012.075184","article-title":"Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma","volume":"98","author":"Barnes","year":"2013","journal-title":"Haematologica"},{"key":"B191","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1634\/theoncologist.2009-0178","article-title":"FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma","volume":"15","author":"Kwitkowski","year":"2010","journal-title":"Oncologist"},{"key":"B192","first-page":"275","article-title":"Temsirolimus (Torisel (R)): first approved drug for the advanced mantle cell lymphoma","volume":"33","author":"Grossheim","year":"2010","journal-title":"Onkologie"},{"key":"B193","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/1471-2407-13-308","article-title":"A Phase I\/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor temsirolimus added to standard therapy of rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma - the STORM trial","volume":"13","author":"Witzens-Harig","year":"2013","journal-title":"BMC Cancer"},{"key":"B194","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1002\/hon.2438_52","article-title":"Safety and clinical activity of temsirolimus in combination with rituximab and DHAP in patients with relapsed or refractory diffuse large B-cell lymphoma - report of the prospective, multicenter Phase II STORM trial","volume":"128","author":"Witzens-Harig","year":"2016","journal-title":"Blood"},{"key":"B195","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2165\/11585040-000000000-00000","article-title":"Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects","volume":"34","author":"Sofroniadou","year":"2011","journal-title":"Drug Saf"},{"key":"B196","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1517\/14740338.2013.752814","article-title":"Adverse events associated with mTOR inhibitors","volume":"12","author":"Pallet","year":"2013","journal-title":"Expert Opin Drug Saf"},{"key":"B197","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.trre.2014.03.002","article-title":"Strategies for the management of adverse events associated with mTOR inhibitors","volume":"28","author":"Kaplan","year":"2014","journal-title":"Transplant Rev"},{"key":"B198","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0002-9440(10)64897-3","article-title":"Detection of BCL2 rearrangements in follicular lymphoma","volume":"160","author":"Aster","year":"2002","journal-title":"Am J Pathol"},{"key":"B199","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3109\/10428190009148399","article-title":"Clinical significance of the t(14;18) and BCL2 overexpression in follicular large cell lymphoma","volume":"36","author":"Weisenburger","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"B200","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3109\/10428199909083379","article-title":"BCL2 overexpression in diffuse large B-cell lymphoma","volume":"34","author":"Monni","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"B201","first-page":"738","volume":"85","year":"1998","journal-title":"Bull Du Cancer"},{"key":"B202","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1039\/C5OB02080H","article-title":"Targeting anti-apoptotic Bcl2 proteins with scyllatoxin-based BH3 domain mimetics","volume":"14","author":"Harris","year":"2016","journal-title":"Org Biomol Chem"},{"key":"B203","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/cpt.553","article-title":"Targeting BCL2 with BH3 mimetics: basic science and clinical application of venetoclax in chronic lymphocytic leukemia and related B cell malignancies","volume":"101","author":"Roberts","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"B204","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3389\/fonc.2018.00636","article-title":"Targeting the Bcl-2 family in B cell lymphoma","volume":"8","author":"Adams","year":"2018","journal-title":"Front Oncol"},{"key":"B205","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.1182\/blood-2007-12-129833","article-title":"Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma","volume":"111","author":"Paoluzzi","year":"2008","journal-title":"Blood"},{"key":"B206","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13045-015-0224-3","article-title":"ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development","volume":"8","author":"Cang","year":"2015","journal-title":"J Hematol Oncol"},{"key":"B207","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1182\/blood-2007-11-124487","article-title":"Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis","volume":"112","author":"Stolz","year":"2008","journal-title":"Blood"},{"key":"B208","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.1158\/1078-0432.CCR-17-3004","article-title":"Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas","volume":"24","author":"Pham","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B209","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"key":"B210","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"key":"B211","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1056\/NEJMc1805135","article-title":"Venetoclax-rituximab in chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"key":"B212","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1200\/JCO.18.01580","article-title":"Fixed duration of venetoclax-rituximab in relapsed\/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO Phase III study","volume":"37","author":"Kater","year":"2019","journal-title":"J Clin Oncol"},{"key":"B213","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1182\/blood-2018-184","article-title":"MURANO trial establishes feasibility of time-limited Venetoclax-Rituximab (VenR) combination therapy in Relapsed\/Refractory (R\/R) Chronic Lymphocytic Leukemia (CLL)","volume":"132","author":"Seymour","year":"2018","journal-title":"Blood"},{"key":"B214","first-page":"4315","article-title":"Disease and patient characteristics, patterns of care, toxicities, and outcomes of Chronic Lymphocytic Leukemia (CLL) patients treated with venetoclax: a multicenter study of 204 patients","volume":"130","author":"Mato","year":"2017","journal-title":"Blood"},{"key":"B215","first-page":"59","article-title":"Integrated safety analysis of venetoclax monotherapy in Chronic Lymphocytic Leukemia (CLL)","volume":"101","author":"Davids","year":"2016","journal-title":"Haematologica"},{"key":"B216","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood.V128.22.2033.2033","article-title":"Detailed safety analysis of venetoclax combined with rituximab in patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"128","author":"Brander","year":"2016","journal-title":"Blood"},{"key":"B217","first-page":"4","article-title":"The American Society of Hematology\u221246th Annual Meeting and Exposition. HDAC, Flt and farnesyl transferase inhibitors","volume":"8","author":"Evans","year":"2005","journal-title":"IDrugs"},{"key":"B218","doi-asserted-by":"publisher","first-page":"3958","DOI":"10.1158\/1078-0432.CCR-08-2785","article-title":"Clinical studies of histone deacetylase inhibitors","volume":"15","author":"Prince","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B219","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.3390\/molecules20033898","article-title":"Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents","volume":"20","author":"Mottamal","year":"2015","journal-title":"Molecules"},{"key":"B220","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/S1470-2045(15)00584-7","article-title":"Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, Phase 1 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"B221","first-page":"175","article-title":"Phase 1 trial of Cudc-907, a novel, oral dual inhibitor of Hdac and Pi3k: updated assessment of patients with relapsed or refractory diffuse large B-cell lymphoma, including double expressor lymphoma","volume":"101","author":"Younes","year":"2016","journal-title":"Haematologica"},{"key":"B222","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1182\/blood.V122.21.4363.4363","article-title":"A first-in-man Phase 1 study Of CUDC-907, a first-in-class chemically-designed dual inhibitor Of PI3K and HDAC in patients with refractory or relapsed lymphoma and multiple myeloma","volume":"122","author":"Younes","year":"2013","journal-title":"Blood"},{"key":"B223","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/S1470-2045(11)70265-0","article-title":"Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, Phase 2 trial","volume":"12","author":"Younes","year":"2011","journal-title":"Lancet Oncol"},{"key":"B224","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1517\/13543784.2011.577737","article-title":"Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor","volume":"20","author":"Boumber","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"B225","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/bjh.14698","article-title":"A Phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma","volume":"178","author":"Batlevi","year":"2017","journal-title":"Br J Haematol"},{"key":"B226","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/bjh.13195","article-title":"Phase I\/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation","volume":"168","author":"Straus","year":"2015","journal-title":"Br J Haematol"},{"key":"B227","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/bjh.12819","article-title":"A multicentre Phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma","volume":"165","author":"Ogura","year":"2014","journal-title":"Br J Haematol"},{"key":"B228","doi-asserted-by":"publisher","first-page":"85","DOI":"10.15430\/JCP.2015.20.2.85","article-title":"Dual inhibitors against topoisomerases and histone deacetylases","volume":"20","author":"Seo","year":"2015","journal-title":"J Cancer Prev"},{"key":"B229","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.3390\/ph3092751","article-title":"Clinical toxicities of histone deacetylase inhibitors","volume":"3","author":"Subramanian","year":"2010","journal-title":"Pharmaceuticals"},{"key":"B230","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1016\/S2352-3026(18)30216-3","article-title":"Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a Phase 1 dose escalation and expansion trial","volume":"6","author":"Nastoupil","year":"2019","journal-title":"Lancet Haematol"},{"key":"B231","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1016\/S2352-3026(18)30217-5","article-title":"Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a Phase 1\/2a study","volume":"6","author":"Younes","year":"2019","journal-title":"Lancet Haematol"},{"key":"B232","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3109\/10428194.2014.911859","article-title":"Phase 1\/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcgammaRIIIa patients with previously treated follicular lymphoma","volume":"56","author":"Ganjoo","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"B233","doi-asserted-by":"publisher","first-page":"3698","DOI":"10.1182\/blood-2011-09-378323","article-title":"Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study","volume":"119","author":"Czuczman","year":"2012","journal-title":"Blood"},{"key":"B234","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","article-title":"Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, Phase 2 trial","volume":"15","author":"Westin","year":"2014","journal-title":"Lancet Oncol"},{"key":"B235","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1182\/blood-2017-09-804641","article-title":"Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a Phase 2 consortium trial","volume":"131","author":"Bartlett","year":"2018","journal-title":"Blood"},{"key":"B236","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"key":"B237","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"key":"B238","doi-asserted-by":"publisher","first-page":"6446","DOI":"10.1158\/1078-0432.CCR-09-1339","article-title":"Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma","volume":"15","author":"Ansell","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B239","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1200\/JCO.2012.48.3685","article-title":"Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international Phase II trial","volume":"31","author":"Armand","year":"2013","journal-title":"J Clin Oncol"},{"key":"B240","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","article-title":"Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, Phase 2 trial","volume":"17","author":"Wang","year":"2016","journal-title":"Lancet Oncol"},{"key":"B241","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.3324\/haematol.2017.169656","article-title":"Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"102","author":"Younes","year":"2017","journal-title":"Haematologica"},{"key":"B242","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.3324\/haematol.2017.172882","article-title":"CUDC-907 in relapsed\/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded Phase I trial","volume":"102","author":"Oki","year":"2017","journal-title":"Haematologica"},{"key":"B243","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13045-017-0537-5","article-title":"Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed\/progressed after or were refractory\/intolerant to ibrutinib (MCL-004)","volume":"10","author":"Wang","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B244","doi-asserted-by":"publisher","first-page":"e109","DOI":"10.1016\/S2352-3026(18)30018-8","article-title":"Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, Phase 2 trial","volume":"5","author":"Jerkeman","year":"2018","journal-title":"Lancet Haematol"},{"key":"B245","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.7150\/jca.24577","article-title":"Current status and future directions of cancer immunotherapy","volume":"9","author":"Zhang","year":"2018","journal-title":"J Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00443\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T05:00:41Z","timestamp":1694926841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00443\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,4]]},"references-count":245,"alternative-id":["10.3389\/fonc.2019.00443"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.00443","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,4]]},"article-number":"443"}}